Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Cash (2016 - 2025)

Historic Change in Cash for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $7.1 million.

  • Marker Therapeutics' Change in Cash rose 49439.68% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 21733.55%. This contributed to the annual value of $4.1 million for FY2024, which is 2257.88% up from last year.
  • As of Q3 2025, Marker Therapeutics' Change in Cash stood at $7.1 million, which was up 49439.68% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Change in Cash ranged from a high of $43.2 million in Q1 2021 and a low of -$14.7 million during Q1 2022
  • Over the past 5 years, Marker Therapeutics' median Change in Cash value was -$3.5 million (recorded in 2024), while the average stood at -$126812.1.
  • As far as peak fluctuations go, Marker Therapeutics' Change in Cash surged by 128269.47% in 2021, and later tumbled by 13401.27% in 2022.
  • Quarter analysis of 5 years shows Marker Therapeutics' Change in Cash stood at -$5.2 million in 2021, then fell by 20.86% to -$6.3 million in 2022, then surged by 62.47% to -$2.4 million in 2023, then skyrocketed by 531.45% to $10.2 million in 2024, then tumbled by 30.07% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, -$1.9 million for Q2 2025, and -$5.5 million during Q1 2025.